150 related articles for article (PubMed ID: 11681418)
1. The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome.
Miyamoto N; Sugita K; Goi K; Inukai T; Lijima K; Tezuka T; Kojika S; Nakamura M; Kagami K; Nakazawa S
Leukemia; 2001 Nov; 15(11):1758-68. PubMed ID: 11681418
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
Sun X; Layton JE; Elefanty A; Lieschke GJ
Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
[TBL] [Abstract][Full Text] [Related]
3. Expression of thrombopoietin receptor and its functional role in human B-precursor leukemia cells with 11q23 translocation or Philadelphia chromosome.
Iijima K; Sugita K; Inukai T; Goi K; Tezuka T; Uno K; Sato H; Kagami K; Nakazawa S
Leukemia; 2000 Sep; 14(9):1598-605. PubMed ID: 10995006
[TBL] [Abstract][Full Text] [Related]
4. Jak2 is involved in c-Myc induction by Bcr-Abl.
Xie S; Lin H; Sun T; Arlinghaus RB
Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase 2: a critical target in chronic myelogenous leukemia.
Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
[TBL] [Abstract][Full Text] [Related]
6. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells.
Ruchatz H; Coluccia AM; Stano P; Marchesi E; Gambacorti-Passerini C
Exp Hematol; 2003 Apr; 31(4):309-15. PubMed ID: 12691918
[TBL] [Abstract][Full Text] [Related]
7. PRL-induced ERalpha gene expression is mediated by Janus kinase 2 (Jak2) while signal transducer and activator of transcription 5b (Stat5b) phosphorylation involves Jak2 and a second tyrosine kinase.
Frasor J; Barkai U; Zhong L; Fazleabas AT; Gibori G
Mol Endocrinol; 2001 Nov; 15(11):1941-52. PubMed ID: 11682625
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
9. TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS.
Koschmieder S; Hofmann WK; Kunert J; Wagner S; Ballas K; Seipelt G; Hoelzer D; Ottmann OG; Kalina U
Leukemia; 2001 Jun; 15(6):942-9. PubMed ID: 11417481
[TBL] [Abstract][Full Text] [Related]
10. Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cell lines.
Sato S; Honma Y; Hozumi M; Hayashi Y; Matsuo Y; Shibata K; Omura S; Hino K; Tomoyasu S; Tsuruoka N
Leuk Res; 1994 Mar; 18(3):221-8. PubMed ID: 8139288
[TBL] [Abstract][Full Text] [Related]
11. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
[TBL] [Abstract][Full Text] [Related]
12. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.
De Vos J; Jourdan M; Tarte K; Jasmin C; Klein B
Br J Haematol; 2000 Jun; 109(4):823-8. PubMed ID: 10929036
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
14. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
15. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
[TBL] [Abstract][Full Text] [Related]
16. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
[TBL] [Abstract][Full Text] [Related]
17. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
Okabe M; Kunieda Y; Miyagishima T; Kobayashi M; Kurosawa M; Itaya T; Sakurada K; Miyazaki T
Leuk Lymphoma; 1993 Jul; 10(4-5):307-16. PubMed ID: 7693103
[TBL] [Abstract][Full Text] [Related]
18. [Inhibition of constitutively activated Jak3 and induction of apoptosis in NALM-6 cell line].
Hu W; Zhang C; Zhang P; Wei D; Zhao Z; Cai M
Hua Xi Yi Ke Da Xue Xue Bao; 2002 Jan; 33(1):25-7. PubMed ID: 12599420
[TBL] [Abstract][Full Text] [Related]
19. Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1 ;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia.
Rambaldi A; Attuati V; Bassan R; Neonato MG; Viero P; Battista R; Di Bona E; Rossi G; Pogliani E; Ruggeri M; Amaru R; Rivolta A; Giudici G; Biondi A; Barbui T
Leuk Lymphoma; 1996 May; 21(5-6):457-66. PubMed ID: 9172811
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor.
Honma Y; Matsuo Y; Hayashi Y; Omura S
Int J Cancer; 1995 Mar; 60(5):685-8. PubMed ID: 7860143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
